DOCSLIB.ORG

EUA) of REGEN-COVTM (Casirivimab and Imdevimab

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COVTM (casirivimab and imdevimab) AUTHORIZED USE TREATMENT The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, REGEN-COV (casirivimab and imdevimab) co-formulated product and REGEN-COV (casirivimab and imdevimab) supplied as individual vials to be administered together, for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adult and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Limitations of Authorized Use • REGEN-COV (casirivimab and imdevimab) is not authorized for use in patients: - who are hospitalized due to COVID-19, OR - who require oxygen therapy due to COVID-19, OR - who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity. • Monoclonal antibodies, such as REGEN-COV, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. POST-EXPOSURE PROPHYLAXIS The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, REGEN-COV (casirivimab and imdevimab) co-formulated product and REGEN-COV (casirivimab and imdevimab) supplied as individual vials to be administered together, in adult and pediatric individuals (12 years of age and older weighing at least 40 kg) for post-exposure prophylaxis of COVID-19 in individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, and are: • not fully vaccinated1 or who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications2) and 1 Individuals are considered to be fully vaccinated 2 weeks after their second vaccine dose in a 2-dose series (such as the Pfizer or Moderna vaccines), or 2 weeks after a single-dose vaccine (such as Johnson & Johnson’s Janssen vaccine). See this website for more details: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully- vaccinated.html#vaccinated 2 See this website for more details: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully- vaccinated-people.html Page 1 of 52 - have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per Centers for Disease Control and Prevention (CDC)3 or - who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes, prisons) [see Limitations of Authorized Use (1.2)]. Limitations of Authorized Use • Post-exposure prophylaxis with REGEN-COV (casirivimab and imdevimab) is not a substitute for vaccination against COVID-19. • REGEN-COV (casirivimab and imdevimab) is not authorized for pre-exposure prophylaxis for prevention of COVID-19. RECENT MAJOR CHANGES • Dosage and Administration (Box, Section 2.4, Section 3, Section 19): addition of co-packaged carton Revised 09/2021 • Dosage and Administration (Section 2.4): addition of 5% Dextrose as diluent Revised 09/2021 • Antiviral Resistance (Box and Section 15): addition of information on susceptibility of SARS-CoV-2 variants to REGEN-COV (Tables 9 and 10) Revised 08/2021 • Authorized Use: addition of new indication for post-exposure prophylaxis of COVID-19 Revised 07/2021 • Dosage and Administration (Box, and Section 2.2): updated authorized dosage for post-exposure prophylaxis of COVID-19 Revised 07/2021 • Authorized Use: expanded the definition of progression of severe COVID-19 to include death Revised 06/2021 • Dosage and Administration (Box, and Section 2.2): updated authorized dosage Revised 06/2021 • Dosage and Administration (Box, Section 2.2 and 2.4): updated with subcutaneous route of administration as an alternative for those who cannot receive intravenous infusion Revised 06/2021 • Dosage and Administration (Box, Section 2.2 and 2.4): updated with co-formulation Revised 06/2021 • Warnings: Hypersensitivity Including Anaphylaxis and Infusion- Related Reactions (Section 5.1): addition of vasovagal reactions Revised 06/2021 • Overall Safety Summary, Clinical Trials Experience (Section 6.1): addition of Phase 3 results and safety with subcutaneous dosing Revised 06/2021 • Clinical Trial Results and Supporting Data for EUA, Mild to Moderate COVID-19 (Section 18.1): addition of Phase 3 data for the authorized dose Revised 06/2021 • Dosage and Administration (Box and Section 2.1): updated 3 Close contact with an infected individual is defined as: being within 6 feet for a total of 15 minutes or more, providing care at home to someone who is sick, having direct physical contact with the person (hugging or kissing, for example), sharing eating or drinking utensils, or being exposed to respiratory droplets from an infected person (sneezing or coughing, for example). See this website for additional details: https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html Page 2 of 52 high risk criteria for patient selection Revised 05/2021 • Dose Preparation and Administration Instructions (Section 2.4): provides updated minimum infusion times based on size of infusion bag used Revised 03/2021 • New proprietary name: REGEN-COV Revised 02/2021 • Warnings: Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions (Section 5.1) – addition of new symptoms Revised 02/2021 • Warnings: Clinical Worsening After REGEN-COV Administration (Section 5.2) – new warning added Revised 02/2021 REGEN-COV has been authorized by FDA for the emergency uses described above. REGEN-COV is not FDA-approved for these uses. REGEN-COV is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of REGEN-COV under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Treatment This EUA is for the use of the unapproved product, REGEN-COV (casirivimab and imdevimab) co-formulated product and REGEN-COV (casirivimab and imdevimab) supplied as individual vials to be administered together, for the treatment of mild to moderate COVID-19 in adult and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death [see Limitations of Authorized Use (1.1)]. Post-Exposure Prophylaxis This EUA is for the use of the unapproved product, REGEN-COV (casirivimab and imdevimab) co-formulated product and REGEN-COV (casirivimab and imdevimab) supplied as individual vials to be administered together, in adult and pediatric individuals (12 years of age and older weighing at least 40 kg) for post-exposure prophylaxis of COVID-19 in individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, and are: • not fully vaccinated1 or who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications2) and - have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per Center for Disease Control and Prevention (CDC)3 or - who are at high risk of exposure to an individual infected with SARS- CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes, prisons) [see Limitations of Authorized Use (1.2)]. Page 3 of 52 Criteria for Identifying High Risk Individuals The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40 kg) at higher risk for progression to severe COVID-19: • Older age (for example, age ≥65 years of age) • Obesity or being overweight (for example, BMI >25 kg/m2, or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm) • Pregnancy • Chronic kidney disease • Diabetes • Immunosuppressive disease or immunosuppressive treatment • Cardiovascular disease (including congenital heart disease) or hypertension • Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension) • Sickle cell disease • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies) • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)) Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and authorization of REGEN-COV under the EUA is not limited to the medical conditions or factors listed above. For additional information on
Recommended publications
  • Uniqure N.V. Paasheuvelweg 25A 1105BP Amsterdam the Netherlands +1-339-970-7000

    Uniqure N.V. Paasheuvelweg 25A 1105BP Amsterdam the Netherlands +1-339-970-7000

    uniQure N.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands +1-339-970-7000 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on September 14, 2017 To the Shareholders of uniQure N.V.: Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Extraordinary Meeting”) of uniQure N.V., a public company with limited liability ( naamloze vennootschap ) under the laws of the Netherlands (the “Company,” “uniQure,” and “we”), will be held on September 14, 2017, at 9:30 a.m., Central European Summer Time, at the Company’s principal executive offices located at Paasheuvelweg 25a, 1105BP Amsterdam, the Netherlands, for the following purposes: I. Opening and announcements; II. Appointment of Jeremy P. Springhorn, Ph.D. as a non-executive director (voting proposal no. 1); III. Appointment of Madhavan Balachandran as a non-executive director (voting proposal no. 2); IV Any other business that may properly come before the meeting or any adjournment of the meeting; and V. Closing of the meeting. Each person authorized to attend the Extraordinary Meeting may inspect the Agenda at the office of uniQure. Our Board of Directors (our “Board”) recommends that you vote “FOR” each of the voting proposals noted above. The record date is set at the close of business on August 17, 2017 EST and, therefore, only the Company’s shareholders of record at the close of business on August 17, 2017 EST are entitled to receive this notice (this “Notice”) and to vote at the Extraordinary Meeting and any adjournment thereof. Only shareholders who have given notice in writing to the Company by September 12, 2017 of their intention to attend the Extraordinary Meeting in person are entitled to attend the Extraordinary Meeting in person.
  • Communicable Diseases of Children

    Communicable Diseases of Children

    15 Communicable Diseases of Children Dennis 1. Baumgardner The communicable diseases of childhood are a source of signif­ from these criteria, the history, physical examination, and ap­ icant disruption for the family and a particular challenge to the propriate laboratory studies often define one of several other family physician. Although most of these illnesses are self­ more specific respiratory syndromes as summarized in limited and without significant sequelae, the socioeconomic Table 15.1.3-10 impact due to time lost from school (and work), costs of medi­ Key points to recall are that significant pharyngitis is not cal visits and remedies, and parental anxiety are enormous. present with most colds, that most colds are 3- to 7-day Distressed parents must be treated with sensitivity, patience, illnesses (except for lingering cough and coryza for up to and respect for their judgment, as they have often agonized for 2 weeks), and that abrupt worsening of symptoms or develop­ hours prior to calling the physician. They are usually greatly ment of high fever mandates prompt reevaluation. Tonsillo­ reassured when given a specific diagnosis and an explanation of pharyngitis (hemolytic streptococci, Epstein-Barr virus, the natural history of even the most minor syndrome. adenovirus, Corynebacterium) usually involves a sore throat, It is essential to promptly differentiate serious from benign fever, erythema of the tonsils and pharynx with swelling or disorders (e.g., acute epiglottitis versus spasmodic croup), to edema, and often headache and cervical adenitis. In addition to recognize serious complications of common illnesses (e.g., var­ the entities listed in Table 15.1, colds must also be differenti­ icella encephalitis), and to recognize febrile viral syndromes ated from allergic rhinitis, asthma, nasal or respiratory tree (e.g., herpangina), thereby avoiding antibiotic misuse.
  • Patient Care Through Telepharmacy September 2016

    Patient Care Through Telepharmacy September 2016

    Patient Care through Telepharmacy September 2016 Gregory Janes Objectives 1. Describe why telepharmacy started and how it has evolved with technology 2. Explain how telepharmacy is being used to provide better patient care, especially in rural areas 3. Understand the current regulatory environment around the US and what states are doing with regulation Agenda ● Origins of Telepharmacy ● Why now? ● Telepharmacy process ● Regulatory environment ● Future Applications Telepharmacy Prescription verification CounselingPrescription & verification Education History Origins of Telepharmacy 1942 Australia’s Royal Flying Doctor Service 2001 U.S. has first state pass telepharmacy regulation 2003 Canada begins first telepharmacy service 2010 Hong Kong sees first videoconferencing consulting services US Telepharmacy Timeline 2001 North Dakota first state to allow 2001 Community Health Association in Spokane, WA launches program 2002 NDSU study begins 2003 Alaska Native Medical Center program 2006 U.S. Navy begins telepharmacy 2012 New generation begins in Iowa Question #1 What was the first US state to allow Telepharmacy? a) Alaska b) North Dakota c) South Dakota d) Hawaii Question #1 What was the first US state to allow Telepharmacy? a) Alaska b) North Dakota c) South Dakota d) Hawaii NDSU Telepharmacy Study Study from 2002-2008 ● 81 pharmacies ○ 53 retail and 28 hospital ● Rate of dispensing errors <1% ○ Compared to national average of ~2% ● Positive outcomes, mechanisms could be improved Source: The North Dakota Experience: Achieving High-Performance
  • Preventive Health Care

    Preventive Health Care

    PREVENTIVE HEALTH CARE DANA BARTLETT, BSN, MSN, MA, CSPI Dana Bartlett is a professional nurse and author. His clinical experience includes 16 years of ICU and ER experience and over 20 years of as a poison control center information specialist. Dana has published numerous CE and journal articles, written NCLEX material, written textbook chapters, and done editing and reviewing for publishers such as Elsevire, Lippincott, and Thieme. He has written widely on the subject of toxicology and was recently named a contributing editor, toxicology section, for Critical Care Nurse journal. He is currently employed at the Connecticut Poison Control Center and is actively involved in lecturing and mentoring nurses, emergency medical residents and pharmacy students. ABSTRACT Screening is an effective method for detecting and preventing acute and chronic diseases. In the United States healthcare tends to be provided after someone has become unwell and medical attention is sought. Poor health habits play a large part in the pathogenesis and progression of many common, chronic diseases. Conversely, healthy habits are very effective at preventing many diseases. The common causes of chronic disease and prevention are discussed with a primary focus on the role of health professionals to provide preventive healthcare and to educate patients to recognize risk factors and to avoid a chronic disease. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 1 Policy Statement This activity has been planned and implemented in accordance with the policies of NurseCe4Less.com and the continuing nursing education requirements of the American Nurses Credentialing Center's Commission on Accreditation for registered nurses. It is the policy of NurseCe4Less.com to ensure objectivity, transparency, and best practice in clinical education for all continuing nursing education (CNE) activities.
  • A Tool to Help Clinicians Do What They Value Most

    A Tool to Help Clinicians Do What They Value Most

    Health Information Technology: a Tool to Help Clinicians Do What They Value Most Health care professionals like you play a vital role in improving the health outcomes, quality of care, and the health care experience of patients. Health information technology (health IT) is an important tool that you can use to improve clinical practice and the health of your patients. Health IT can help health care professionals to do what you do best: provide excellent care to your patients. Research shows that when patients are Health IT encompasses a wide range of electronic tools that can help you: engaged in their health care, it can lead to • Access up-to-date evidence-based clinical guidelines and decision measurable improvements in safety and support quality. • Improve the quality of care and safety of your patients Source: Agency for Healthcare Research and Quality (AHRQ) • Provide proactive health maintenance for your patients • Better coordinate patients’ care with other providers through the secure and private sharing of clinical information. Health IT can help you to solve clinical problems with real-time data Quality improvement and clinical decision support rely on information about your patient population being readily available in digital form. Health IT can help you monitor your patients’ health status and make specific and targeted recommendations to improve your patients’ health. Access to real-time data through electronic health records and health IT will help you: A MAJORITY OF PROVIDERS • Use clinical decision support to highlight care options tailored to believe that electronic health information your patients has the potential to improve the quality of patient care and care coordination.
  • Laryngitis from Reflux: Prevention for the Performing Singer

    Laryngitis from Reflux: Prevention for the Performing Singer

    Laryngitis from Reflux: Prevention for the Performing Singer David G. Hanson, MD, FACS Jack J. Jiang, MD, PhD Laryngitis in General Laryngitis is the bane of performers and other professionals who depend on their voice for their art and livelihood. Almost every person has experienced acute laryngitis, usually associated with a viral upper- respiratory infection. Whenever there is inflammation of the vocal fold epithelium, there is an effect on voice quality and strength. Therefore, it is important to understand the factors that can cause laryngitis, especially the preventable causes of laryngitis. Laryngitis is a generic term for inflammation or irritation of the laryngeal tissues. The inflammation can be caused by any kind of injury, including infection, smoking, contact with caustic or acidic substance, allergic reaction, or direct trauma. Inflammatory response of the tissues includes leakage of fluid from blood vessels with edema or swelling, congregation of white blood cells, which release mediators of inflammation, and engorgement of the blood vessels. Most commonly laryngitis occurs from viral infection of the laryngeal epithelial lining associated with a typical cold. The viral infection is almost always quickly conquered by the body's immune system and lasts at most a few days. This kind of acute laryngitis rarely causes any long-term problem unless the vocal folds are damaged by overuse during the illness. Examination of the larynx will show whether the vocal folds are inflamed and allows some prediction of the degree of risk for damage. Other infections of the larynx are fortunately not common but include infections with bacteria and other organisms.
  • Librarianship and the Philosophy of Information

    Librarianship and the Philosophy of Information

    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Library Philosophy and Practice (e-journal) Libraries at University of Nebraska-Lincoln July 2005 Librarianship and the Philosophy of Information Ken R. Herold Hamilton College Follow this and additional works at: https://digitalcommons.unl.edu/libphilprac Part of the Library and Information Science Commons Herold, Ken R., "Librarianship and the Philosophy of Information" (2005). Library Philosophy and Practice (e-journal). 27. https://digitalcommons.unl.edu/libphilprac/27 Library Philosophy and Practice Vol. 3, No. 2 (Spring 2001) (www.uidaho.edu/~mbolin/lppv3n2.htm) ISSN 1522-0222 Librarianship and the Philosophy of Information Ken R. Herold Systems Manager Burke Library Hamilton College Clinton, NY 13323 “My purpose is to tell of bodies which have been transformed into shapes of a different kind.” Ovid, Metamorphoses Part I. Library Philosophy Provocation Information seems to be ubiquitous, diaphanous, a-categorical, discrete, a- dimensional, and knowing. · Ubiquitous. Information is ever-present and pervasive in our technology and beyond in our thinking about the world, appearing to be a generic ‘thing’ arising from all of our contacts with each other and our environment, whether thought of in terms of communication or cognition. For librarians information is a universal concept, at its greatest extent total in content and comprehensive in scope, even though we may not agree that all information is library information. · Diaphanous. Due to its virtuality, the manner in which information has the capacity to make an effect, information is freedom. In many aspects it exhibits a transparent quality, a window-like clarity as between source and patron in an ideal interface or a perfect exchange without bias.
  • The Anti-Essentialism Paper

    The Anti-Essentialism Paper

    The New Pragmatism, Anti-essentialism, and What is Universal: It’s The Situation All The Way Down C. F. Abel Stephen F. Austin State University [email protected] The New Pragmatism, Anti-essentialism, and What is Universal: It’s The Situation All The Way Down C. F. Abel Stephen F. Austin State University [email protected] A well-known scientist once gave a public lecture on astronomy. He described how the Earth orbits around the sun and how the sun, in turn, orbits around the center of a vast collection of stars called our galaxy. At the end of the lecture, a little old lady at the back of the room got up and said: "What you have told us is rubbish. The world is really a flat plate supported on the back of a giant tortoise." The scientist gave a superior smile before replying, "What is the tortoise standing on?" "You're very clever, young man," said the old lady. "But it's turtles all the way down!" Introduction “New Pragmatism” attacks the very foundation of pragmatic thought by denying that we may ever have any definitive experience. As what we are experiencing is up for grabs, we can never know any situation that we may encounter, and we are left to ground both our knowledge and our values in our language games alone. This paper argues that this set of claims is founded on two errors, one regarding the nature of language games and the other regarding the nature of deconstruction. The “Old Pragmatism,” by way of contrast, is non-essentialist but not anti- essentialist, and it resolves the problem of how we might know “the situation,” given the subjectivity of our observations and the contingencies of our language games, by suggesting that our experiences can be understood as existing in, and constituted by, the totality of their particular instances or modes at the time of inquiry.
  • METAPHYSICS and the WORLD CRISIS Victor B

    METAPHYSICS and the WORLD CRISIS Victor B

    METAPHYSICS AND THE WORLD CRISIS Victor B. Brezik, CSB (The Basilian Teacher, Vol. VI, No. 2, November, 1961) Several years ago on one of his visits to Toronto, M. Jacques Maritain, when he was informed that I was teaching a course in Metaphysics, turned to me and inquired with an obvious mixture of humor and irony indicated by a twinkle in the eyes: “Are there some students here interested in Metaphysics?” The implication was that he himself was finding fewer and fewer university students with such an interest. The full import of M. Maritain’s question did not dawn upon me until later. In fact, only recently did I examine it in a wider context and realize its bearing upon the present world situation. By a series of causes ranging from Kant’s Critique of Pure Reason in the 18th century and the rise of Positive Science in the 19th century, to the influence of Pragmatism, Logical Positivism and an absorbing preoccupation with technology in the 20th century, devotion to metaphysical studies has steadily waned in our universities. The fact that today so few voices are raised to deplore this trend is indicative of the desuetude into which Metaphysics has fallen. Indeed, a new school of philosophers, having come to regard the study of being as an entirely barren field, has chosen to concern itself with an analysis of the meaning of language. (Volume XXXIV of Proceedings of the American Catholic Philosophical Association deals with Analytical Philosophy.) Yet, paradoxically, while an increasing number of scholars seem to be losing serious interest in metaphysical studies, the world crisis we are experiencing today appears to be basically a crisis in Metaphysics.
  • Administering a Subcutaneous Injection

    Administering a Subcutaneous Injection

    Inject medication slowly and release skin Will the injection hurt? Children may describe a pinching/stinging or bee-sting sensation during Our Lady’s Children’s Leave needle in place for 5-10 seconds after and just after the injection. It is normal for the Hospital, Crumlin, Dublin injecting medication, if possible injection site to be a little red and tender. It is 12 Remove needle swiftly and smoothly expected that children may be afraid of injections. It is important to be honest and explain the Wipe area gently with cotton wool, do not rub injection in a manner that they can understand. ….where children’s health comes first as this may be sore. Apply a plaster if needed. How to reduce any discomfort: ADVICE FOR • Prepare your child, explain why this is necessary PARENTS/GUARDIANS/CHILDREN and how you will give the injection Step 4. Dispose of the Needle/Syringe • Use distraction and play to amuse your child Administering a • Encourage them to practice on their teddy or doll. For infants, give them a soother/comforter if Subcutaneous Injection Dispose of needle and syringe immediately into they use one a sharps bin • Ensure clothing over the injection site is not tight My child has a bleeding disorder: seek medical advice before giving injections to your child. Auto-injector: Some children use an automatic injection device, often called a ‘rocket’. Specific Instructions: ……………………………………………………………………… ………………………………………………………………………. Developed by: Naomi Bartley, Clinical Placement Coordinator. CONTACT DETAILS Example of an Auto-Injector st Date issued: July 2014, October 2012 : 1 edn. Ward / Dept. Name: _________________ Date of review: July 2017 Telephone: ___________________ Follow the manufacture’s instructions for ©2014, Our Lady’s Children’s Hospital Crumlin, Dublin 12.
  • Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry1

    Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry1

    Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) July 2018 Procedural Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353 Email: [email protected] https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication, Outreach and Development Center for Biologics Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 71, Room 3128 Silver Spring, MD 20993-0002 Phone: 800-835-4709 or 240-402-8010 Email: [email protected] https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication and Education CDRH-Division of Industry and Consumer Education Center for Devices and Radiological Health Food and Drug Administration 10903 New Hampshire Ave., Bldg. 66, Room 4621 Silver Spring, MD 20993-0002 Phone: 800-638-2041 or 301-796-7100; Fax: 301-847-8149 Email: [email protected] https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) July 2018 Procedural Contains Nonbinding Recommendations TABLE OF CONTENTS I.
  • Interim Recommendations for Use of the Moderna Mrna-1273 Vaccine Against COVID-19

    Interim Recommendations for Use of the Moderna Mrna-1273 Vaccine Against COVID-19

    Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 Interim guidance First issued 25 January 2021 Updated 15 June 2021 Background This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its extraordinary meeting on 21 January 2021 (1) and updated during its extraordinary meeting on 27 May 2021(2). Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Working Group website. The guidance is based on the evidence summarised in the Background document on the Moderna mRNA-1273 vaccine against COVID-19 (3) and the background paper on COVID-19 disease and vaccines (4). Annexes which include GRADE and evidence-to-recommendations (ETR) tables have also been updated to reflect the updated recommendations. All referenced documents are available on the SAGE COVID-19 webpage: https://www.who.int/groups/strategic- advisory-group-of-experts-on-immunization/covid-19-materials. These interim recommendations refer to the mRNA-1273 vaccine, manufactured by Moderna. The vaccine is also known as COVID-19 Vaccine Moderna. In the subsequent text the vaccine will be referred to as mRNA-1273. On 30 April 2021, mRNA-1273 was granted WHO’s Emergency Use Listing (EUL). Methods SAGE applies the principles of evidence-based medicine and has set in place a thorough methodological process for issuing and updating recommendations (5). A detailed description of the methodological processes as they apply to COVID-19 vaccines can be found in the SAGE evidence framework for COVID-19 vaccines (6).